{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-104135","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.943771+00:00","generated_at":"2026-05-15T13:39:16.628044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Korro Bio reports FY2025 net loss $117.3M, nominates KRRO-121 for UCD/HE; $85M PIPE extends runway to H2 2028","bullets":["FY2025 net loss $117.3M vs $83.6M in FY2024, driven by $30.9M non-cash impairment charges on KRRO-110 termination.","Cash $85.2M at Dec 31, 2025; plus $85M private placement in Mar 2026 extends runway into H2 2028.","Nominated KRRO-121 for UCD and HE; regulatory filing expected H2 2026.","GalNAc AATD program achieved >90% in vivo RNA editing; candidate nomination Q2 2026.","Collaboration revenue $6.4M from Novo Nordisk (paused); R&D expenses $65.6M, G&A $28.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-104135","json":"https://secwatch.observer/filing/0001193125-26-104135.json","markdown":"https://secwatch.observer/filing/0001193125-26-104135.md","text":"https://secwatch.observer/filing/0001193125-26-104135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/0001193125-26-104135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/krro-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:39:16.628044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}